Amsterdam, December 23rd 2025 – This year again, Holland Capital has taken important steps within the Technology and Healthcare sectors. Our clear investment strategy, combined with close and active collaboration with entrepreneurs and advisors, has resulted in the further expansion of our portfolio and strong progress within our Holland Capital Growth & Buy-Out Fund V. In addition, we launched the fundraising for our new Holland Capital Venture & Growth Fund VI this autumn. With this new fund, our objective is to strengthen companies in their growth, based on a clear positioning and with a strong focus on value creation.

With this update, we are pleased to inform you about the key developments in 2025 and to share our ambitions for 2026. Thank you for the pleasant collaboration, and we look forward to continuing this in the coming year.

Our results in 2025 underline our growth ambitions

For Holland Capital, 2025 was characterized by further professionalization, a steady deal flow, and the strengthening of our teams in both the Netherlands and Germany.

Highlights 2025

• Number of platform deals: 4 (including 1 in Germany)
• Number of add-on acquisitions: 10 (including 2 in Germany)
• Number of exits: 4
• Number of new colleagues: 11

Sector focus and hands-on value creation 

Our specialized sector teams focus on Technology and Healthcare, across both venture and buy-out investments. Thanks to our in-depth market knowledge and many years of experience, we can actively support entrepreneurs in realizing their growth ambitions.

Holland Capital invests in an entrepreneurial and hands-on manner. Together with the management teams of our portfolio companies, we define strategic objectives. Our operational team then provides hands-on support in achieving these goals, ranging from digitalization and commercial acceleration to organizational professionalization.

Which companies would we like to connect with?

Companies active in the Technology and Healthcare sectors

Growth & Buy-Out

• Healthy profitability: EBITDA between EUR 250k – 10m;
• Smaller companies: considered as add-on acquisitions for our existing portfolio companies.

Venture & Growth

• Start-ups and scale-ups: EBITDA < EUR 250k;
• Negative cash flow (in accelerated growth scenarios);
• Proven product-market fit and business model;
• Growth capital requirement between EUR 1–5m (or more in combination with a co-investor).

Collaboration with advisors, essential at every stage

Corporate finance advisors play an important role in our processes. Advisors provide structure, safeguard interests, and support entrepreneurs in making well-considered decisions. We ensure that the advisor’s position is clear and safeguarded throughout each process.

We prefer to engage with entrepreneurs at an early stage. This helps them gain a better understanding of what a partnership with a private equity firm entails and allows room to explore strategic options in a timely manner.

What does Holland Capital bring in 2026?

• Flexible transaction structures
  We actively think along on the most suitable structure for the company and its shareholders. Both new capital injections and share acquisitions are possible, in both majority and minority situations.
• Deal certainty and an efficient process
  Thanks to our sector expertise, we can quickly arrive at a clear valuation. We also place great importance on a careful process in which partnership, transparency, and mutual respect are central.
• Clear communication towards advisors
  We value being involved at an early stage by advisors and ensure that their role, interests, and added value remain safeguarded throughout the entire process.

Do you know an entrepreneur for whom our approach could be of interest?
We would be pleased to connect. Together, we realize sustainable value creation for businesses. We look forward to continuing our collaboration in 2026!

The Holland Capital Team